[go: up one dir, main page]

Richards et al. - Google Patents

Polycythemia Vera

Richards et al.

View PDF
Document ID
7148106623209128485
Author
Richards N
Lawrence N
Singh I
Butina M

External Links

Snippet

Polycythemia vera is a rare, acquired clonal disorder of the hematopoietic stem cells resulting in unregulated proliferation of erythropoiesis leading to an accumulation of red cells. The main complications of the disorder arise from hyperviscosity and an increased risk …
Continue reading at www.ijbls.org (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Similar Documents

Publication Publication Date Title
Vannucchi Management of myelofibrosis
Grand et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
US8536225B2 (en) Therapeutic methods employing nitric oxide precursors
US20170119715A1 (en) Therapeutic methods employing nitric oxide precursors
Loscocco et al. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives
Takenaka et al. Recent advances in the diagnosis and management of primary myelofibrosis
Hamad et al. Myeloproliferative neoplasms
O'Brien et al. Chronic myelogenous leukemia
Evseev et al. Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH
Borsa et al. Autophagy preserves hematopoietic stem cells by restraining MTORC1-mediated cellular anabolism
KR20220155379A (en) Methods of Treating IDH1 Inhibitor-Resistant Subjects
Trachtenberg et al. Pain as an emergent issue in thalassemia
Hazenberg et al. Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study
Campbell et al. Myeloproliferative neoplasms
Berglund et al. The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma
Richards et al. Polycythemia Vera
Rivell et al. Effectiveness and safety of high‐dose cyclophosphamide as salvage therapy for high‐risk multiple myeloma and plasma cell leukemia refractory to new biological agents
Wood et al. Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome
Au et al. Clinicopathological features and outcome of late relapses of natural killer cell lymphomas 10–29 years after initial remission
SROUR et al. Allogeneic Cell Transplantation for Myeloproliferative Neoplasms
Kirienko et al. MPN-225 next generation sequencing (NGS) in the diagnosis, prognosis and features of the disease in Ph-negative myeloproliferative neoplasms
Luo et al. Patients with thalassemia in the United States
Point Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH
Hernaningsih Literature review of hematology division the mechanism of imanitib resistance in chronic myeloid leukemia
Associate et al. MPN-221 Management Parameters of Myeloproliferative Neoplasm (MPN) With JAKV617F Mutation During Conception Optimizing the Outcome